miR-30a as Potential Therapeutic by Targeting TET1 through Regulation of the Hydroxymethlation of Drp-1 Promoter in IPF

• DOI: 10.20944/preprints201701.0074.v1
• Publication Date: 2017-01-18T12:39:17Z
• Authors: Songzi Zhang; Huizhu Liu; Yuxia Liu; Jie Zhang; Hongbo Li; Weili Liu; Guohong Cao; Pan Xu; Jinjin Zhang; Changjun Lv; Xiaodong Song
• Keywords: 0303 health sciences; 03 medical and health sciences; molecular_biology; 3. Good health

Several recent studies have indicated that miR-30a plays critical roles in various biological processes and diseases. However, the mechanism of participation regulation idiopathic pulmonary fibrosis (IPF) is ambiguous. Our previous study demonstrated may function as a novel therapeutic target for lung fibrosis by blocking mitochondrial fission, which dependent on dynamin-related protein-1 (Drp-1). regulatory between Drp-1 has yet to be investigated. In addition, whether can act potential not been verified vivo. this study, expression IPF patients was evaluated. Computational analysis dual luciferase reporter system assay were used identify gene miR-30a, cell transfection confirm relationship. Ten-eleven translocation 1 (TET1) validated direct mimic/inhibitor significantly reduced/increased TET1 protein. Further experiment interference TET1(siRNA) could inhibit hydroxymethlation promoter. Finally, agomir designed applied validate effect base pairing with complementary sites 3′ untranslated region regulate Furthermore, IPF.